In Parkinson’s disease patients the brain cells start to die and sometimes also lead to aspiration pneumonia. This is life-threatening and even take their lives. But a recent study helps to plan better treatment methods for Parkinson’s disease (PD).
It tells about a blood test for inflammatory and cell senescence biomarkers that can predict the cognitive decline and identify the motor progression and early dementia in Parkinson’s disease (PD) patients. The detailed findings related to this study can be studied in the Journal of Parkinson’s Disease.
The lead investigator, Gabriele Saretzki, of the Biosciences Institute and The Ageing Biology Centre at the Campus for Ageing and Vitality of Newcastle University, Newcastle upon Tyne, UK explains that the chances of cognitive impairment are more likely to develop in the Parkinsons disease (PD) patients than the age-matched controls. And dementia is approached to 80 percent in Parkinson’s disease patients.
Parkinsons disease (PD) is also linked with inflammation. The previously published studies predict that more pro-inflammatory profile in the blood causes more rapid clinical progression.
The researchers have discovered the markers of cell senescence that is associated with neurodegeneration and inflammation. It is noted that blood-derived markers are associated with cognitive and motor function.
In the Cognitive Impairments in Cohorts with Longitudinal Evaluation-Parkinson’s Disease (ICICLE-PD) study more than a hundred newly diagnosed Parkinson’s disease patients have participated and many of them undergo cognitive and physical assessments for two years.
Researchers have analyzed some cellular senescence markers whether these markers are predictive of motor and cognitive progression for the next two years or not. These markers are p16, telomere length (TL), and p21. The expression of these markers is measured at two-time points, baseline and 18 months. And 5 inflammatory markers are selected from accessible baseline data.
The shorter telomeres were observed in Parkinson’s disease (PD) patients at baseline and 18 months. Parkinson’s disease (PD) patients with dementia had also shorter telomeres compared to those who were dementia-free at that time. P16 levels cause a faster decline in cognitive and motor progression.
Study more-Chinese Coronavirus Deaths Cross 1000 Cases
Dr. Saretzki finds that there is a need for the improvement of suitable blood-based biomarkers to anticipate outcomes is important for neurodegenerative diseases like Parkinson’s disease (PD) which progress over numerous years.
The identified markers should be approved in further examinations but could help with arranging more focused management on the executives for patients earlier in the disease course. Besides, a superior comprehension of the biological changes that foresee disease course has suggestions for conceivable future therapies for the disease.
The study author, a leading names in Clinical Neuroscience from the University of Cambridge, and at Addenbrooke’s Hospital, Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, University of Cambridge, Roger Barker, thinks that this study is very helpful to plan better treatment methods for Parkinson’s disease for future. It further tells that this could be done easily, even by using a simple blood test.